Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Essler

Showing results (31-40 of 208) with videos related to

Pageof 21
Sort By:
Clinical Nuclear Medicine|September 9, 2016
Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617Xiao Wei, Carl Schlenkhoff, Claudia Sopora, et al.
Leukemia & Lymphoma|November 3, 2020
Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces <sup>18</sup>F-FDG uptake and increases sensitivity towards ABT-737-induced apoptosisGabriel Buschner, Benedikt Feuerecker, Sabine Spinner, et al.
Clinical Nuclear Medicine|July 19, 2017
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate CancerXiao Wei, Carl Schlenkhoff, Bettina Schwarz, et al.
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India|March 1, 2017
[<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with IpilimumabAnna Yordanova, Carl Schlenkhoff, Holger Palmedo, et al.
Clinical Nuclear Medicine|November 13, 2013
First experience with image-guided resection of paragangliomaIngo Einspieler, Alexander Novotny, Asli Okur, et al.
Nuklearmedizin. Nuclear Medicine|November 3, 2020
Tumor heterogeneity for differentiation between liver tumors and normal liver tissue in 18F-FDG PET/CTLynn Hartmann, Lena Bundschuh, Norbert Zsótér, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2020
Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?Susanne Lütje, Georg Feldmann, Markus Essler, et al.
Clinical Nuclear Medicine|February 25, 2016
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate CancerCarl Diedrich Schlenkhoff, Florian Gaertner, Markus Essler, et al.
Clinical Nuclear Medicine|July 13, 2016
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate CancerHojjat Ahmadzadehfar, Carl Diedrich Schlenkhoff, Sebastian Rogenhofer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 25, 2007
Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)sFlorian C Gaertner, Robert Luxenhofer, Birgit Blechert, et al.
Pageof 21

Showing results (31-40 of 208) with videos related to

Sort By:
Pageof 21
Clinical Nuclear Medicine|September 9, 2016
Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617Xiao Wei, Carl Schlenkhoff, Claudia Sopora, et al.
Leukemia & Lymphoma|November 3, 2020
Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces <sup>18</sup>F-FDG uptake and increases sensitivity towards ABT-737-induced apoptosisGabriel Buschner, Benedikt Feuerecker, Sabine Spinner, et al.
Clinical Nuclear Medicine|July 19, 2017
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate CancerXiao Wei, Carl Schlenkhoff, Bettina Schwarz, et al.
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India|March 1, 2017
[<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with IpilimumabAnna Yordanova, Carl Schlenkhoff, Holger Palmedo, et al.
Clinical Nuclear Medicine|November 13, 2013
First experience with image-guided resection of paragangliomaIngo Einspieler, Alexander Novotny, Asli Okur, et al.
Nuklearmedizin. Nuclear Medicine|November 3, 2020
Tumor heterogeneity for differentiation between liver tumors and normal liver tissue in 18F-FDG PET/CTLynn Hartmann, Lena Bundschuh, Norbert Zsótér, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2020
Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?Susanne Lütje, Georg Feldmann, Markus Essler, et al.
Clinical Nuclear Medicine|February 25, 2016
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate CancerCarl Diedrich Schlenkhoff, Florian Gaertner, Markus Essler, et al.
Clinical Nuclear Medicine|July 13, 2016
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate CancerHojjat Ahmadzadehfar, Carl Diedrich Schlenkhoff, Sebastian Rogenhofer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 25, 2007
Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)sFlorian C Gaertner, Robert Luxenhofer, Birgit Blechert, et al.
Pageof 21